PuSH - Publikationsserver des Helmholtz Zentrums München: Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Karches, C.H.* ; Benmebarek, M.R.* ; Schmidbauer, M.L.* ; Kurzay, M.* ; Klaus, R.* ; Geiger, M.* ; Rataj, F.* ; Cadilha, B.L.* ; Lesch, S.* ; Heise, C.* ; Murr, R.* ; vom Berg, J.* ; Jastroch, M. ; Lamp, D. ; Ding, J.* ; Duewell, P.* ; Niederfellner, G.* ; Sustmann, C.* ; Endres, S.* ; Klein, C.* ; Kobold, S.*

Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy.

Clin. Cancer Res. 25, 5890-5900 (2019)

Postprint

DOI

PMC

	Open Access Green

Abstract
Metriken
Zusatzinfos

Purpose: Genetically engineered T cells are powerful anticancer treatments but are limited by safety and specificity issues. We herein describe an MHC-unrestricted modular platform combining autologous T cells, transduced with a targetable synthetic agonistic receptor (SAR), with bispecific antibodies (BiAb) that specifically recruit and activate T cells for tumor killing.Experimental Design: BiAbs of different formats were generated by recombinant expression. T cells were retrovirally transduced with SARs. T-cell activation, proliferation, differentiation, and T-cell-induced lysis were characterized in three murine and human tumor models in vitro and in vivo.Results: Murine T cells transduced with SAR composed of an extracellular domain EGFRvIII fused to CD28 and CD3 zeta signaling domains could be specifically recruited toward murine tumor cells expressing EpCAM by anti-EGFRvIII x anti-EpCAM BiAb. BiAb induced selective antigen-dependent activation, proliferation of SAR T cells, and redirected tumor cell lysis. Selectivity was dependent on the monovalency of the antibody for EGFRvIII. We identified FAS ligand as a major mediator of killing utilized by the T cells. Similarly, human SAR T cells could be specifically redirected toward mesothelin-expressing human pancreatic cancer cells. In vivo, treatment with SAR T cells and BiAb mediated antitumoral activity in three human pancreatic cancer cell xenograft models. Importantly, SAR activity, unlike CAR activity, was reversible in vitro and in vivo.Conclusions: We describe a novel ACT platform with antitumor activity inmurine and human tumor models with a distinct mode of action that combines adoptive T-cell therapy with bispecific antibodies.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

8.911

1.847